SEARCH

SEARCH BY CITATION

References

  • 1
    Markert ML . Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991; 3: 4581.
  • 2
    Al-Kali A , Gandhi V , Ayoubi M , Keating M , Ravandi F . Forodesine: review of preclinical and clinical data. Future Oncol 2010; 6: 12117.
  • 3
    Duvic M , Forero-Torres A , Foss F , Olsen E , Kim Y . Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study (Abstract). Blood 2007; 110: Abstract 122.
  • 4
    Cheson BD , Horning SJ , Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 124453.
  • 5
    Olsen EA , Kim YH , Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 310915.
  • 6
    Olsen E , Vonderheid E , Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 171322.
  • 7
    Pui CH , Evans WE . Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 60515.
  • 8
    López-Guillermo A , Cid J , Salar A et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 84955.
  • 9
    Gisselbrecht C , Gaulard P , Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998; 92: 7682.
  • 10
    Vose J , Armitage J , Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 412430.
  • 11
    O'Connor OA , Pro B , Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 11829.
  • 12
    Prince HM , Duvic M , Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 18707.
  • 13
    Piekarz RL , Frye R , Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 54107.
  • 14
    Whittaker SJ , Demierre MF , Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 448591.
  • 15
    Yamamoto K , Utsunomiya A , Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 15918.